Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
MIMirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc. (MIRM)

NASDAQ Global Market · Currency in USD
$80.39 ▼ -2.71 (-3.26%)
At close: Oct 23, 4:00 PM ET. Market closed.
$80.39 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$83.10
Open
$82.70
Day's Range
$80.24 – $83.00
52 Week Range
$63.23 – $130.00
Volume
788,213
Avg. Volume
795,020
Market Cap
$5.22B
Beta (5Y Monthly)
0.49
PE Ratio (TTM)
--
EPS (TTM)
-$13.57
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$153.20

Profile: Mirum Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
433
CEO
Christopher Peetz

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.49 · Revenue est. $178.08M
DateEst.Actual
Aug 5, 2026-$0.74-$1.06Miss
May 6, 2026-$0.40-$13.43Miss
Feb 25, 2026$0.02-$0.11Miss
Nov 4, 2025-$0.10$0.05Beat
Aug 6, 2025-$0.31-$0.12Beat
May 7, 2025-$0.39-$0.30Beat

Analyst view

Consensus price target
$153.20 ▲ +90.6%
Range $130.00 – $200.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on MIRM and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.